Physician profile
Michael Bishop
NPI 1548252091
$2,480.67
in general payments reported to CMS, 2019-2025
22 companies · $341 in 2025
The $341 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $224 · 2021: $95.81 · 2022: $202 · 2023: $390 · 2024: $510 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $465.12 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $316.73 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $203.60 | 2024-2025 | |
| Pfizer INC. | $198.11 | 2019-2023 | |
| Ucb, INC. | $181.78 | 2024-2025 | Nayzilam |
| Merck Sharp & Dohme LLC | $168.24 | 2019-2022 | |
| Cranial Technologies, INC | $142.60 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $138.71 | 2021-2023 | Qelbree |
| Neos Therapeutics, Lp | $128.49 | 2019-2024 | Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $110.11 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $65.24 | 2025 | Neffy |
| Genentech USA, INC. | $63.85 | 2020-2021 | |
| Kaleo, INC. | $50.71 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $44.32 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.90 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $36.12 | 2019-2024 | Dyanavel Xr |
| Shire North American Group INC | $35.60 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.90 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $19.56 | 2019 | |
| Aytu Biopharma, INC. | $17.46 | 2024 | Karbinal |
| Kowa Pharmaceuticals America, INC. | $16.24 | 2025 | Zoryve |
| Circassia INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.